Yuekang Pharmaceutical: Injection of Moresildevir has passed the generic drug consistency evaluation.

Yuekang Pharmaceuticals Announcement: The company has received the Drug Supplementary Application Approval Notice for the injection of Ganciclovir issued by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency. Injection of Ganciclovir is mainly used to treat cytomegalovirus infections in immunocompromised patients at risk of life or vision, as well as to prevent cytomegalovirus infections in organ transplant patients. This consistency evaluation is beneficial for expanding the company's market share and enhancing market competitiveness.